...

Conference Track

From Podium to Practice: Clinical Impact of New Data From EASL 2011

Source: CCO Independent Conference Coverage of the 2011 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

REALIZE: Telaprevir Plus PegIFN/RBV Associated With Significant Increases in SVR in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV
Previous Treatment Response Categorization Better Predictor of SVR Following Telaprevir-Based Therapy Than Response to 4-Week PegIFN/RBV Lead-in Phase
REALIZE Subanalysis: IL28B Genotype Not Significantly Associated With SVR in Treatment-Experienced Patients Receiving Telaprevir-Based Triple Therapy for HCV Infection
Telaprevir-Resistant HCV Variants Present at Time of Treatment Failure Replaced by Wild-Type Virus Over Time in Majority of Patients
Boceprevir Plus PegIFN/RBV Safe and Effective in Genotype 1 HCV–Infected Patients With Advanced Fibrosis/Cirrhosis
IL28B Genotype Predicts Lead-in Response, Likelihood of Shortened Therapy in SPRINT-2 and RESPOND-2 Phase III Boceprevir Trials
Among Genotype 1 HCV–Infected Patients Not Achieving SVR With Boceprevir-Based Regimen, Resistance-Associated Variants More Common in Those With Poor Response to 4-Week PegIFN/RBV Lead-in
Addition of Alisporivir to PegIFN/RBV Yields Superior Efficacy vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV
SILEN-C1: High Rate of Rapid and Sustained Virologic Response With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV Infection
Ritonavir-Boosted Danoprevir Plus PegIFN/RBV Produces Potent Antiviral Activity in Null Responders Infected With Genotype 1b HCV but High Rate of Viral Breakthrough With Genotype 1a
ASPIRE Interim Data: TMC435 Plus PegIFN/RBV Demonstrates High Rates of Response Through Week 24 in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV
JUMP-C Interim Analysis: Virologic Response to Mericitabine (RG7128) Combined With PegIFN/RBV for 24 Weeks in Treatment-Naive Patients Infected With Genotype 1/4 HCV
In Previous Null Responders With Genotype 1 HCV Infection, BMS-790052 Plus BMS-650032 Produces SVR in 36% Receiving Dual Therapy, 100% Receiving Concomitant PegIFN/RBV
ZENITH Interim Results: Potent Antiviral Activity With 12 Weeks of VX-222 + Telaprevir + PegIFN/RBV Quad Therapy, but Virologic Breakthrough Common With VX-222 + Telaprevir Dual Therapy
PSI-938 and PSI-7977 Purine and Pyrimidine Nucleotide Analogues Demonstrate Favorable Safety/Tolerability and Robust 14-Day Antiviral Activity Alone and in Combination Against Genotype 1 HCV
EMERGE Week 12 Interim Analysis: PegIFN Lambda Associated With Higher Virologic Response Rates in Patients With Genotype 1/4 HCV and Similar Rates in Patients With Genotype 2/3 HCV vs PegIFN alfa-2a, With Fewer Dose Reductions
IL28B Genotype May Predict Response to PegIFN Treatment in Patients Chronically Infected With HBeAg-Positive Hepatitis B
Biochemical and Histopathologic Outcomes Not Improved With Addition of Metformin or Losartan to Rosiglitazone vs Rosiglitazone Alone in Patients With NASH
SOCRATES: Combining Sorafenib and TACE for Treatment of Advanced Hepatocellular Carcinoma Yields Promising Efficacy Results

Expert Analysis

From Podium to Practice: Clinical Impact of New Data From EASL 2011

Begin the Expert Analysis

Faculty:

Graham R. Foster, FRCP, PhD
Paul Y. Kwo, MD
Stefan Zeuzem, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply new data on the safety and efficacy of direct-acting antiviral combinations with and without peginterferon/ribavirin for the treatment of hepatitis C virus infection
Integrate the latest clinical data on investigational strategies for the management of nonalcoholic steatohepatitis and hepatocellular carcinoma into clinical practice
Describe the predictive role of IL28B genotype in patients receiving peginterferon therapy for the treatment of hepatitis B or peginterferon/ribavirin in combination with direct-acting antiviral agents for the treatment of hepatitis C
Recount recent study findings on the safety and efficacy of host-targeted antiviral agents for the treatment of hepatitis C

CREDIT INFORMATION

Release Date: 6/6/11

Expiration Date: 6/5/12

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.